XML 67 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
Product Revenue (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Net Product Sales
The following table summarizes total collaboration revenue recognized for the years ended December 31, 2024, 2023 and 2022:
 Year Ended December 31, 
 202420232022
Revenue from Collaborators$$$
Research and development service revenue— 79,431 46,822 
Right to access intellectual property revenue— 104,477 104,994 
Material rights revenue— 71,980 — 
Other 30,695 13,039 9,493 
Total30,695 268,927 161,309 
The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December 31, 2024, 2023 and 2022:
 Year Ended December 31, 
 202420232022
$$$
Research and development service revenue— 72,278 39,655 
Other 1
2,113 5,067 9,493 
Total2,113 77,345 49,148 
1 Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.
The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December 31, 2024, 2023 and 2022:
 Year Ended December 31, 
 202420232022
$$$
Research and development service revenue— 7,153 7,167 
Right to access intellectual property revenue— 104,477 104,994 
Material rights revenue— 71,980 — 
Other 2
18,259 8,859 — 
Total18,259 192,469 112,161 
2 Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.
The table below presents the Company’s net product sales for the years ended December 31, 2024, 2023 and 2022.
 Year Ended December 31,
 202420232022
 $$$
Product revenue - gross4,786,744 2,718,969 1,438,440 
Less: Rebates and sales returns(1,007,198)(529,117)(183,828)
Product revenue - net3,779,546 2,189,852 1,254,612 
The following table disaggregates net product revenue by product for the years ended December 31, 2024, 2023 and 2022.
Year Ended December 31,
202420232022
$$$
BRUKINSA®
2,644,226 1,290,396 564,651 
Tislelizumab620,836 536,620 422,885 
XGEVA®
224,403 92,828 63,398 
BLINCYTO®
74,331 54,342 36,107 
KYPROLIS®
66,171 39,799 13,696 
POBEVCY®
53,509 56,547 38,124 
REVLIMID®
36,028 76,018 79,049 
Other60,042 43,302 36,702 
Total product revenue - net3,779,546 2,189,852 1,254,612 
Schedule of Accrued Sales Rebates and Returns
The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December 31, 2024 and 2023.
 Rebates, Returns and Other DeductionsContra AR AccrualsTotal
 $$
Balance at December 31, 202241,817 8,580 50,397 
Amounts charged against product revenue275,031 254,086 529,117 
Payments and credits(176,912)(232,231)(409,143)
Balance at December 31, 2023139,936 30,435 170,371 
Amounts charged against product revenue491,756 515,442 1,007,198 
Payments and credits(396,092)(495,178)(891,270)
Balance at December 31, 2024235,600 50,699 286,299